[{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"AGEN1223","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Agenus \/ Not Applicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Balstilimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Not Applicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Balstilimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Not Applicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"AGENT-797","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Agenus \/ Not Applicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Betta Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"Balstilimab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"Agenus \/ Betta Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Betta Pharmaceuticals"},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"AGEN1181","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Agenus \/ Not Applicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Betta Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Balstilimab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Agenus \/ Betta Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Betta Pharmaceuticals"},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Balstilimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Not Applicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Balstilimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Not Applicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Balstilimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Not Applicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"AGENT-797","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Agenus \/ Not Applicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"MK-4830","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Agenus \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Merck"},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"AGEN1181","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Not Applicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"iNKT cell therapy","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Agenus \/ Not Applicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"AGEN1181","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Not Applicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Allogeneic iNKT cell therapy","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Agenus \/ Not Applicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Balstilimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Not Applicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"AGEN1777","moa":"TIGIT","graph1":"Oncology","graph2":"Phase I","graph3":"Agenus","amount2":1.5600000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.5600000000000001,"dosageForm":"","sponsorNew":"Agenus \/ Bristol Myers","highestDevelopmentStatusID":"6","companyTruncated":"Agenus \/ Bristol Myers"},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Balstilimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Not Applicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"AGEN1777","moa":"TIGIT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Agenus","amount2":1.5600000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.5600000000000001,"dosageForm":"","sponsorNew":"Agenus \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Agenus \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Balstilimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Not Applicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Balstilimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Not Applicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"AGEN1777","moa":"TIGIT","graph1":"Oncology","graph2":"Phase I","graph3":"Agenus","amount2":1.5800000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.5800000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Agenus \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Agenus \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"AGEN1181","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Not Applicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"AGEN1181","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Not Applicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"AGN1181","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Agenus \/ Not Applicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Balstilimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Not Applicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Targovax","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"QS-21 Stimulon","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Agenus \/ Agenus","highestDevelopmentStatusID":"5","companyTruncated":"Agenus \/ Agenus"},{"orgOrder":0,"company":"Agenus","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"AGEN2373","moa":"CD137","graph1":"Oncology","graph2":"Phase I","graph3":"Agenus","amount2":1.8500000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.8500000000000001,"dosageForm":"Intravenous","sponsorNew":"Agenus \/ Gilead","highestDevelopmentStatusID":"6","companyTruncated":"Agenus \/ Gilead"},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"AGEN1571","moa":"ILT4 ant","graph1":"Oncology","graph2":"Phase I","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Agenus \/ Not Applicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Oxford Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Balstilimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Agenus \/ Agenus","highestDevelopmentStatusID":"6","companyTruncated":"Agenus \/ Agenus"},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Balstilimab","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Not Applicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Balstilimab","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Not Applicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"AGEN1571","moa":"ILT2","graph1":"Oncology","graph2":"Phase I","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Agenus \/ Not Applicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Balstilimab","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Not Applicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Balstilimab","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Agenus \/ Not Applicable"},{"orgOrder":0,"company":"Agenus","sponsor":"VBI Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"Balstilimab","moa":"GB\/pp65 antigen","graph1":"Oncology","graph2":"Preclinical","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Agenus \/ VBI Vaccines","highestDevelopmentStatusID":"4","companyTruncated":"Agenus \/ VBI Vaccines"},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Balstilimab","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Not Applicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Balstilimab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Not Applicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Balstilimab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Not Applicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Balstilimab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Not Applicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Balstilimab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Not Applicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Balstilimab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Not Applicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Balstilimab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Not Applicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Balstilimab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Not Applicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"AGEN1777","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Agenus","amount2":1.5600000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.5600000000000001,"dosageForm":"Infusion","sponsorNew":"Agenus \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Agenus \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Balstilimab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Not Applicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Financing","leadProduct":"Balstilimab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Agenus \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Balstilimab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Not Applicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Balstilimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Agenus \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Agenus

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : AGEN1181 (botensilimab) a novel innate/adaptive immune activator, is a multifunctional Fc-enhanced anti-CTLA-4, given in combination with balstilimab in microsatellite stable colorectal cancer.

                          Brand Name : AGEN1181

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          July 18, 2024

                          Lead Product(s) : Botensilimab,Balstilimab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : AGEN1181 (botensilimab) a novel innate/adaptive immune activator, is a multifunctional Fc-enhanced anti-CTLA-4, given in combination with balstilimab in microsatellite stable colorectal cancer.

                          Brand Name : AGEN1181

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          May 16, 2024

                          Lead Product(s) : Botensilimab,Balstilimab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Financing supports AGEN1181 and AGEN2034 Phase 3 for metastatic colorectal cancer without active liver metastases.

                          Brand Name : AGEN1181

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          May 07, 2024

                          Lead Product(s) : Botensilimab,Balstilimab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Ligand Pharmaceuticals

                          Deal Size : $100.0 million

                          Deal Type : Financing

                          blank

                          04

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : AGEN1181 (botensilimab) is a novel innate/adaptive immune activator, a multifunctional Fc-enhanced anti-CTLA-4 with balstilimab (anti-PD-1) for metastatic microsatellite stable colorectal cancer.

                          Brand Name : AGEN1181

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          April 12, 2024

                          Lead Product(s) : Botensilimab,Balstilimab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Under the agreement, Bristol licensed BMS-986442 (AGEN1777), a dual TIGIT and CD96 antagonist with an enhanced Fc region to improve tumor-reactive T cell responses, from Agenus and currently dosed first patient in the phase 2 of the ongoing clinical tria...

                          Brand Name : BMS-986442

                          Molecule Type : Large molecule

                          Upfront Cash : $200.0 million

                          December 11, 2023

                          Lead Product(s) : AGEN1777,Docetaxel,Nivolumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Bristol Myers Squibb

                          Deal Size : $1,560.0 million

                          Deal Type : Licensing Agreement

                          blank

                          06

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : AGEN1181 (botensilimab) a novel innate/adaptive immune activator, is a multifunctional Fc-enhanced anti-CTLA-4 which is given in combination with balstilimab (anti-PD-1) in patients with chemotherapy and/or immunotherapy-resistant tumors.

                          Brand Name : AGEN1181

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          October 10, 2023

                          Lead Product(s) : Botensilimab,Balstilimab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : AGEN1181 (botensilimab) a novel innate/adaptive immune activator, is a multifunctional Fc-enhanced anti-CTLA-4 which is given in combination with balstilimab (anti-PD-1) in patients with chemotherapy and/or immunotherapy-resistant tumors.

                          Brand Name : AGEN1181

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          August 23, 2023

                          Lead Product(s) : Botensilimab,Balstilimab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : AGEN1181 (botensilimab) is a novel innate and adaptive immune activator that binds ctla-4 and has demonstrated activity in cancer patients. it has received fast track designation for colorectal cancer.

                          Brand Name : AGEN1181

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          April 17, 2023

                          Lead Product(s) : Botensilimab,Balstilimab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : AGEN1181 (botensilimab) is a novel innate and adaptive immune activator that binds CTLA-4. The antibody was designed to enhance FcγR effector functions while avoiding complement-related toxicities and has demonstrated activity in cancer patients.

                          Brand Name : AGEN1181

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          February 28, 2023

                          Lead Product(s) : Botensilimab,Balstilimab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : AGEN1181 (botensilimab) a novel innate/adaptive immune activator, is a multifunctional Fc-enhanced anti-CTLA-4 which is given in combination with balstilimab (anti-PD-1) in patients with chemotherapy and/or immunotherapy-resistant tumors.

                          Brand Name : AGEN1181

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          January 23, 2023

                          Lead Product(s) : Botensilimab,Balstilimab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank